Review question
Is combination therapy with anticholinergics, a type of medicine that can relieve abnormal bladder contraction (where a man cannot control when he urinates), and alpha-blockers, a type of medicine that can relax the urethral muscle (the tube that carries urine from the bladder out through the penis during urination), effective and safe for managing urination difficulties and urgency related to enlarged prostate?
Background
Urination difficulties and urgency caused by enlarged prostate (a male organ near the bladder and surrounding a part of the urethra) are common in men. Although alpha-blockers have been used to relieve the urinary symptoms, up to one third of men get no benefit. Combination therapy with alpha-blockers and anticholinergics provides a treatment option for men with urinary symptoms.
Study characteristics
The search is up-to-date to 7 August 2020. We identified 23 studies involving 6285 men. Five studies compared combination therapy with anticholinergics and alpha-blockers versus placebo (a pill with no therapeutic effects). A total of 22 studies compared combination therapy with anticholinergics and alpha-blockers versus alpha-blockers alone. Three studies compared combination therapy with anticholinergics and alpha-blockers versus anticholinergics alone. The follow-up period in the studies ranged from 12 weeks to one year.
Key results
Combination therapy versus placebo: combination therapy with anticholinergics and alpha-blockers was associated with little effect in urinary symptoms and uncertain improvement on quality of life, but combination therapy may increase unwanted side effects.
Combination therapy versus alpha-blockers: combination therapy with anticholinergics and alpha-blockers may have uncertain effects on improvement of urinary symptoms and quality of life compared to alpha-blockers alone. Combination therapy may not increase unwanted side effects.
Combination therapy compared to anticholinergics: combination therapy with anticholinergics and alpha-blockers may be associated with uncertain effects on urinary symptoms, but an improvement in quality of life in comparison with anticholinergics alone. Combination therapy may not increase unwanted side effects.
Quality of the evidence
A majority of included studies were not well conducted or reported, which is why we rated down the certainty of evidence (the confidence to state the conclusion is right) to moderate, low or very low. This means that the true effect may be substantially different from what this review found.
Based on the findings of the review, combination therapy with anticholinergics and alpha-blockers are associated with little or uncertain effects on urologic symptom scores compared to placebo, alpha-blockers, or anticholinergics monotherapy. However, combination therapy may result in an improvement in quality of life compared to anticholinergics monotherapy, but an uncertain effect compared to placebo, or alpha-blockers. Combination therapy likely increases adverse events compared to placebo, but not compared to alpha-blockers or anticholinergics monotherapy. The findings of this review were limited by study limitations, inconsistency, and imprecision. We were unable to conduct any of the predefined subgroup analyses.
Lower urinary tract symptoms (LUTS) due to benign prostatic obstruction (BPO) represent one of the most common clinical complaints in men. Alpha-blockers are widely used as first-line therapy for men with LUTS secondary to BPO, but up to one third of men report no improvement in their LUTS after taking alpha-blockers. Anticholinergics used in addition to alpha-blockers may help improve symptoms but it is uncertain how effective they are.
To assess the effects of combination therapy with anticholinergics and alpha-blockers in men with LUTS related to BPO.
We performed a comprehensive search of medical literature, including the Cochrane Library, MEDLINE, Embase, and trials registries, with no restrictions on the language of publication or publication status. The date of the latest search was 7 August 2020.
We included randomized controlled trials. Inclusion criteria were men with LUTS secondary to BPO, ages 40 years or older, and a total International Prostate Symptom Score of 8 or greater. We excluded trials of men with a known neurogenic bladder due to spinal cord injury, multiple sclerosis, or central nervous system disease, and those examining medical therapy for men who were treated with surgery for BPO. We performed three comparisons: combination therapy versus placebo, combination therapy versus alpha-blockers monotherapy, and combination therapy versus anticholinergics monotherapy.
Two review authors independently screened the literature, extracted data, and assessed risk of bias. We performed statistical analyses using a random-effects model and interpreted data according to the Cochrane Handbook for Systematic Reviews of Interventions. We used the GRADE approach to rate the certainty of evidence.
We included 23 studies with 6285 randomized men across three comparisons. The mean age of participants ranged from 54.4 years to 73.9 years (overall mean age 65.7 years). Of the included studies, 12 were conducted with a single-center setting, while 11 used a multi-center setting. We only found short-term effect (12 weeks to 12 months) of combination therapy based on available evidence.
Combination therapy versus placebo: based on five studies with 2369 randomized participants, combination therapy may result in little or no difference in urologic symptom scores (mean difference (MD) –2.73, 95% confidence interval (CI) –5.55 to 0.08; low-certainty evidence). We are very uncertain about the effect of combination therapy on quality of life (QoL) (MD –0.97, 95% CI –2.11 to 0.16; very low-certainty evidence). Combination therapy likely increases adverse events (risk ratio (RR) 1.24, 95% CI 1.04 to 1.47; moderate-certainty evidence); based on 252 adverse events per 1000 participants in the placebo group, this corresponds to 61 more adverse events (95% CI 10 more to 119 more) per 1000 participants treated with combination therapy.
Combination therapy versus alpha-blockers alone: based on 22 studies with 4904 randomized participants, we are very uncertain about the effect of combination therapy on urologic symptom scores (MD –2.04, 95% CI –3.56 to –0.52; very low-certainty evidence) and QoL (MD –0.71, 95% CI –1.03 to –0.38; very low-certainty evidence). Combination therapy may result in little or no difference in adverse events rate (RR 1.10, 95% CI 0.90 to 1.34; low-certainty evidence); based on 228 adverse events per 1000 participants in the alpha-blocker group, this corresponds to 23 more adverse events (95% CI 23 fewer to 78 more) per 1000 participants treated with combination therapy.
Combination therapy compared to anticholinergics alone: based on three studies with 1218 randomized participants, we are very uncertain about the effect of combination therapy on urologic symptom scores (MD –3.71, 95% CI –9.41 to 1.98; very low-certainty evidence). Combination therapy may result in an improvement in QoL (MD –1.49, 95% CI –1.88 to –1.11; low-certainty evidence). Combination therapy likely results in little to no difference in adverse events (RR 1.26, 95% CI 0.81 to 1.95; moderate-certainty evidence); based on 115 adverse events per 1000 participants in the anticholinergic alone group, this corresponds to 4 fewer adverse events (95% CI 7 fewer to 13 more) per 1000 participants treated with combination therapy.
